In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mylan N.v. (NASDAQ:MYL), reported that Abbott Laboratories has picked up 25,750,000 of common stock as of 2017-03-24.

The acquisition brings the aggregate amount owned by Abbott Laboratories to a total of 25,750,000 representing a 4.81% stake in the company.

For those not familiar with the company, Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them. Its heritage of being a provider of generic pharmaceuticals goes back to its founding in West Virginia in 1961. Today, Mylan is passionate champions for better health around the world with a platform unmatched in the industry. They have one of the broadest and most diverse portfolios, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products. Their healthcare services help patients to access products and adhere to medication regimens to help promote better health outcomes.

A glance at Mylan N.v. (NASDAQ:MYL)’s key stats reveals a current market capitalization of 22.33 Billion based on 535.50 Million shares outstanding and a price at last close of $41.60 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-06-03 Maroon picked up 1,670 at a purchase price of $44.95. This brings their total holding to 22,036 as of the date of the filing.

On the sell side, the most recent transaction saw Abbott unload 44,000,000 shares at a sale price of $41.60. This brings their total holding to 25,750,000.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mylan N.v. (NASDAQ:MYL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.